

# The role of efficacy, safety and cost in ART: choice of the gonadotrophins

Chairman:

J. Cohen (*France*)

Co-chairman:

B. C. Tarlatzis (*Greece*)

Thursday, March 2, 2006,

14.00-16.00

Palazzo Congressi, Auditorium

# IBSA Satellite Symposium

- 14.00 Welcome and introduction
- 14.05 Bioactivity of the HP urinary FSH (Fostimon®) versus the recombinant FSH (Gonal-F®) evaluated by the follicle bioassay  
*R. Cortvrindt (Belgium)*
- 14.25 What's the principle for selecting u-FSH or r-FSH in ART: recent clinical evidences in women undergoing controlled ovarian stimulation for IntraCyttoplasmic Sperm Injection (ICSI).  
*J. Urbancsek (Hungary)*
- 14.45 The choice between recombinant versus urinary gonadotrophins - impact on IVF-treatment costs in Germany.  
*K. Diedrich (Germany)*
- 15.05 In vitro fertilization in France: economic aspects and influence of the gonadotrophin choice (urinary versus recombinant) on cost  
*J. de Mouzon (France)*
- 15.25 Cost influences the choice of gonadotrophins (urinary versus recombinant) used in ART treatment in the United Kingdom  
*E. Iammarrone (UK)*
- 15.45 Discussion and conclusions
- 16.00 End of session

